Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 康美药业股份有限公司（600518）成立于1997年，于2001年在上交所上市；并于2021年引入国有资金及实力产业投资者，成为广东神农氏企业管理合伙企业（有限合伙）实际控制的企业。 公司秉承“新康美，健康美”的经营理念，在国家振兴中医药事业战略的指引下，坚持聚焦主业，持续夯实中医药全产业链布局；并以中药饮片为核心，以智慧药房为抓手，推动实施智慧药房标准化全国示范等五大项目，全面建设“大健康+大平台+大数据+大服务”体系，进一步打造有影响力的中医药全产业链精准服务型“智慧+”大健康产业企业。 康美药业已基本贯穿中医药产业的上、中、下游，上至药材种植、药材交易，下至生产开发、终端销售，业务渗透中医药全产业链的各个关键环节。目前，公司在全国各地拥有近100家涵盖药材种植、中药材交易市场、现代物流中心和产业基地等业务的企业，建设了11个中药饮片和医药现代化生产基地，管理的中药材市场交易规模占全国的60%以上。 公司率先做出多方面的国家标准，包括：制定中药饮片国家标准以及生产管理GMP、小包装、色标管理、炮制等国家标准，参与国家商务部中药材等级分类标准制订；承担编制700多项中医药编码的国家标准，编制和运营国家发改委批准、授权发布的全国唯一的中药材价格指数——康美·中国中药材价格指数，承担药典会动物药中药饮片炮制规范项目等。公司依托中药饮片国家地方联合工程研究中心、中药饮片标准重点研究室、广东省中药饮片工程技术研究开发中心、广东省中药饮片企业重点实验室等开放式创新平台，致力于中药材的种子种苗、种植、标准，中药饮片的炮制工艺、人工智能、炮制标准、规格等级以及中药配方颗粒、中药经典名方、药食同源健康产品、药事服务等中药资源可持续利用研发；获批国际组织认证的CNAS检测中心和CMA检测中心；获得省级及以上科技奖励15项，拥有发明专利、实用新型专利、外观设计专利、软件著作权等知识产权达660项，是国家知识产权优势企业。 康美药业投资管理康美医院、康美中医馆等，与多家医疗机构、药店建立了长期的合作关系；基于全产业链资源优势率先打造的“智慧药房”模式，覆盖广州、深圳、成都、北京、上海、重庆、普宁、昆明、江门等城市，被列为国家中医药服务标准化研究基地，打造了互联网时代就医用药新模式。 公司持续进行产业精准扶贫，积极承担社会责任，先后带动200万药农包括30万贫困农户脱贫致富，为各地合作医疗机构不间断提供短缺药品，持续保障药品及其他大健康产品的供应及服务。 面向未来，新康美将保持战略定力、坚定发展信心，通过有机整合公司的产业布局优势、线上线下协同采购优势、研发制成与质管优势、营销服务优势，在规范经营的基础上进一步推动高质量发展，致力于打造具有全球影响力的中国中医药品牌企业。
Main Business 从事中药饮片、化学药品等的生产与销售，以及外购产品的销售和中药材贸易。
Legal Representative 赖志坚
Top Executives
董事长：赖志坚
董事：夏华悦,方妙双,梁珺,米琪,赖志坚,刘国伟
独立董事：骆涛,曾庆,赖小平
Top 5 Shareholder
Shareholder name Nature Holding Date
广东神农氏企业管理合伙企业（有限合伙）流通A股25.31%30/09/2024
中国建设银行股份有限公司广东省分行限售股+流通A股4.71%30/09/2024
康美药业股份有限公司破产企业财产处置专用账户流通A股2.92%30/09/2024
康美实业投资控股有限公司流通A股1.67%30/09/2024
中国民生银行股份有限公司深圳分行流通A股1.32%30/09/2024
Company Secretary 周云峰
Solicitors 国浩律师(广州)事务所
Auditors 广东正中珠江会计师事务所（特殊普通合伙）
Tel No 0755-33187777
Fax No 0755-86275777
Website www.kangmei.com.cn
Email kangmei@kangmei.com.cn
Company Address
Register: 广东省普宁市揭神路东侧康美中药城
Office: 广东省深圳市福田区下梅林泰科路
Listing Date 19/03/2001
Shares Capital
Shares Capital: 13,863,866,690
Total A Share: 13,863,866,690
Listed A Share: 13,612,928,105
Non-tradable A Share: 250,938,585
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.010
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 0.508
Market Capitalization(RMB) 31.446B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.